ARK also bolstered its holdings in CRISPR Therapeutics AG (NASDAQ: CRSP ), buying 5955 shares valued at $278,574. This genetic medicines company, alongside BEAM, represents ARK’s deepening investment ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.66, moving +1.88% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq ...

A recent discovery could transform our understanding of bone health maintenance and pave the way for potential treatments for ...

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making ...

Using a modified CRISPR-based mechanism, the team led by Prof. Pallob Kundu has developed a stress-activated gene switch that empowers plants to survive extreme heat and microbial attacks.

Researchers at Shanghai Jiao Tong University have produced fertile adult mice from embryos constructed entirely with male ...

CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel ...

Last month, a baby got the world’s first personalized gene-editing treatment. What will this mean for millions of others with ...

US health secretary Robert F Kennedy Jr has pledged to cut red tape and maintain the country's biotech leadership, in spite ...

In a step toward treating mitochondrial diseases, researchers in the Netherlands have successfully edited harmful mutations in mitochondrial DNA using a genetic tool known as a base editor.

Moving toward clinical development, the researchers demonstrated efficient delivery of mRNA mitochondrial base editors using ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will ...